Literature DB >> 24490604

Bosutinib treatment for Philadelphia chromosome-positive leukemias.

Beverly Bethelmie-Bryan1, Katharine Lord, Stacie Holloway, Hanna Jean Khoury.   

Abstract

The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias. Bosutinib has shown activity against all phases of resistant chronic myeloid leukemia that do not harbor the T315I or V299L ABL kinase domain mutations. Bosutinib is overall well tolerated; transient diarrhea is the most common side effect. This article summarizes the pharmacokinetics, pharmacodynamics, safety and efficacy of bosutinib for the treatment of Philadelphia chromosome-positive leukemias.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24490604     DOI： 10.2217/fon.13.268

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  3 in total

1.  Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies.

Authors:  Fernando L Pagan; Yasar Torres-Yaghi; Michaeline L Hebron; Barbara Wilmarth; R Scott Turner; Sara Matar; Dalila Ferrante; Jaeil Ahn; Charbel Moussa
Journal:  Alzheimers Dement (N Y)       Date:  2022-06-01

2.  [Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia].

Authors:  Ying He; Xiumei Zao; Xuehua Wei
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

Review 3.  Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations.

Authors:  Kendra Sweet; Javier Pinilla-Ibarz; Ling Zhang
Journal:  Patient Prefer Adherence       Date:  2014-07-08       Impact factor: 2.711
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.